OC-0487: The extent of synergy between tumor gamma-irradiation and checkpoint-blocking or T cell-recruiting antibodies  by Hettich, M. et al.
S240                 3rd ESTRO Forum 2015 
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Purpose/Objective: Advanced cervical cancer patients 
treated with (chemo-)radiation and MRI-guided adaptive 
brachytherapy (MR-IGABT) have high local control rates with 
acceptable treatment related morbidity. However, nodal 
recurrence is still a matter of concern. The aim of this study 
was to analyze the pattern of nodal failure in patients 
enrolled in the EMBRACE study (www.embracestudy.dk) and 
to explore potential predictive factors.  
Materials and Methods: Eight hundred and fifty-seven 
patients were treated at least 12 months prior to analysis. A 
number of 410 patients were lymph node negative and 406 
patients were lymph node positive at time of diagnosis. 
Lymphadenectomy or nodal debulking was allowed prior to 
(chemo-)radiation. All affected lymph nodes at time of 
external beam radiotherapy (EBRT) were treated within the 
elective field. Additionally, EBRT boosts aiming at the 
macroscopic nodal disease were allowed. 
Frequency analyses of anamnestic, gynaecological and 
histological information, MRI findings and treatment related 
factors were performed for all individual patients as well as 
for the patient groups with or without nodal failure. 
Multivariable analyses were used to explore potential 
predictive factors for nodal failure in all patients, and for the 
groups ‘node positive’ and ‘node negative’ lymph nodes at 
diagnosis. 
Results: During follow up (median 24 months, range, 3-60), 
62 of the 857 patients developed nodal failure (7%), with 70% 
detected within the first year after treatment. Two year 
survival was 65% and 93%, respectively, for patients with and 
without nodal failure. Nodal failure occurred in 5% of the 
patients without positive nodes and in 10% of the patients 
with positive nodes detected on CT, MRI, US, PET-CT or by 
histopathology at time of diagnosis. In the subgroup of 
patients with PET-CT positive or histopathology proven lymph 
nodes, 15% had a nodal failure. Positive nodes at diagnosis 
were mostly located in the pelvis, whereas recurrences 
mainly occurred in the para-aortic (PAO) region (Figure 1). 
Isolated PAO failures were seen in 35% of the patients with 
nodal failure.  
Cox proportional hazard analysis revealed positive lymph 
nodes at diagnosis, haemoglobin level < 6 mmol/L, white 
blood-cell count >10 x 109/L, and chemotherapy < 5 cycles as 
predictive factors for nodal failure. In the 'node positive' 
group FIGO stage was an additional predictive factor. In the 
'node negative' group tumour width appeared to be the only 
prognostic factor for nodal failure. 
Conclusions: The overall rate of nodal recurrences after 
(chemo-)radiation and MR-IGABT in advanced cervical cancer 
is low. The majority of nodal failures are located in the PAO 
region while affected lymph nodes at diagnosis are mostly 
seen in the pelvis. Two-year survival rates are significantly 
lower for patients with nodal failure. Lymph node 
involvement at diagnosis, haemoglobin level, white blood-cell 
count and chemotherapy are predictive for nodal failure. 
OC-0487   
The extent of synergy between tumor gamma-irradiation 
and checkpoint-blocking or T cell-recruiting antibodies 
M. Hettich1, J. Lahoti1, G. Niedermann1 
1University Clinics Freiburg, Dept. of Radiation Oncology, 
Freiburg, Germany  
Purpose/Objective: Combinations of local radiotherapy and 
immunotherapeutics have the potential to enhance local 
tumor control and to synergize in the induction of systemic 
antitumor immune responses. However, the optimal 
dose/fractionation regimens and optimal immunotherapy 
combinations still have to be defined. Here, we 
characterized the T cell responses induced by 
hypofractionated gamma-irradiation in a murine melanoma 
model and evaluated the extent of synergy of local tumor 
irradiation and PD-1 checkpoint-blocking or T cell-recruiting 
antibodies. PD-1 checkpoint-blocking antibodies enhance 
antitumor T cell responses; bispecific T cell-recruiting 
antibodies are capable of redirecting T cells to eradicate 
malignant cells. As monotherapy, both types of 
immunotherapeutics have recently shown dramatic efficacy 
in clinical trials in certain advanced malignancies, but it is 
not well understood to what extent they synergize with local 
tumor irradiation. 
Materials and Methods: We used a subcutaneous flank tumor 
model by employing B16 melanoma cells expressing the 
prototypic tumor stem cell marker CD133, which is also a 
marker for melanoma stem cells. An antagonistic antibody 
blocking the PD-1 immune checkpoint on T cells or a 
bispecific (CD133×CD3) antibody recruiting T cells to CD133+ 
tumor cells was administered after hypofractionated 
irradiation of either small (200–250 mm3) or large (500–750 
mm3) flank melanomas. Endpoints included tumor growth, 
overall survival, and immune infiltrate. 
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Results: Single treatments with either anti-PD-1 checkpoint-
blocking or CD133-specific T cell-recruiting antibodies had 
only very little effect on tumor growth. Hypofractionated 
tumor irradiation alone delayed tumor growth more strongly, 
but also only transiently for about 2 weeks. Hypofractionated 
tumor irradiation induced tumor-specific effector T cells. In 
accordance with this, the double combination of local 
radiotherapy and anti-PD-1 antibody caused long-lasting 
tumor regressions including some complete cures, even in 
mice with large melanomas. Moreover, the cured mice 
remained immune to subsequent rechallenge with rather high 
doses of either CD133+ or CD133– B16 melanoma cells. 
Noteworthy effects were also observed upon administration 
of the bispecific T cell-recruiting antibody into mice with 
irradiated tumors. The underlying mechanisms of these 
observations will be presented at the meeting. 
Conclusions: The study suggests that the evaluation of 
potential synergistic radiotherapy/immunotherapy 
combinations in immunocompetent mouse tumor models can 
provide crucial information for clinical trial planning. 
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High-tech solutions desperately looking for problems, or are 
we really making a difference?  
“Modern radiation oncology is a well-established, cost-
effective and essential component in the curative and 
palliative treatment of malignancy.” A statement no one can 
argue with. The challenge of individualized treatment 
optimization continuously drives research and technology, 
yet we should be careful not to get trapped in the “Cargo 
Cult Science” as described by Richard Feynman. In this 
lecture, the author - coming from a radiotherapy department 
with in its banner the vision: “to offer the optimal and most 
efficient radiation therapy tailored to the individual patient, 
through development and clinical implementation of novel 
irradiation techniques” - takes a critical view on new 
technologies in radiation oncology. New developments are 
more likely to be adopted if they improve the workflow, and 
if the benefits are more favourable, or at least equal to 
current care. However, sometimes it seems as if we are in a 
blind gallop towards increasingly more precise means of 
tumour localization and irradiation, the perception being 
that it is largely driven by vendors rather than the care 
takers’ or patients’ needs. If development moves too fast, 
the focus might be too strong on the innovation itself and less 
on the (safe) implementation. Industry funded research 
doesn’t help much, in that less favourable results do not 
always end up being published, hence inducing a strong bias 
towards a perception that improved treatment delivery 
requires high-tech solutions; whereas sometimes common 
sense might yield equivalent clinical results. Scientific and 
technological progress comes at a significant cost, and many 
concerns exist regarding the value of that progress. Within 
the current state of the economy, health care politicians face 
the difficult challenge to allow progress through efficacy and 
driven by outcomes. What’s even worse is the danger that 
too much focus on sophisticated expensive technology may 
create a double layer health care system where not all 
patients have access to the best of care. In the end what 
counts is the result, not how we got there. Does this mean 
we have to refrain from innovation? Certainly not. Indeed, 
looking back at the technological progress that has been 
realized the last decades (perhaps “century” is more apt), 
this evolution has been translated successfully into clinical 
improvements both in patient cure as well as quality of life 
(with recent developments such as IMRT, IGRT, BCRT, IGBT, 
SBRT, IMPT, etc, as a proof of concept). In conclusion, it is 
safe to state that many good technological solutions are 
being developed as we speak, the challenge is to introduce 
these innovations adapted to the radiotherapy requirements 
(the end-users) … not the other way around. 
  
 
Symposium with Proffered Papers: HPV and cancer and 
radiotherapy (H&N, cervix, vulva, anal)  
 
 
SP-0489   
HPV-transformation in the cervix and at non-cervical sites 
G. Halec1, L. Alemany2, X. Castellsagué2, B. Lloveras3, D. 
Holzinger4, M. Schmitt4, S. Tous2, M. Alejo5, T. Waterboer4, 
F.X. Bosch2, S. De Sanjose2, M. Pawlita4 
1UCLA AIDS Institute, Department of OB/Gyn, Los Angeles, 
USA  
2IDIBELL Catalan Institute of Oncology, Unit of Infections and 
Cancer Cancer Epidemiology Research Program, Barcelona, 
Spain  
3Hospital del Mar Parc de Salut Mar, Pathology department, 
Barcelona, Spain  
4German Cancer Research Center (DKFZ), Infections and 
Cancer Program, Heidelberg, Germany  
5General Hospital d'Hospitalet, Pathology department, 
Barcelona, Spain  
 
Human papillomavirus (HPV) infections are an essential cause 
for virtually all carcinomas of the uterine cervix and subsets 
of other anogenital, oropharyngeal and laryngeal tumors. The 
HPV aetiological contribution differs in each anatomical 
location reflecting differences in natural history and viral 
tissue tropism. Up to 99,9% of cervical, 80% of anal and 30% 
of vulvar cancers have been defined as HPV DNA positive by 
epidemiological studies. In the head-and-neck (H&N) region, 
HPV DNA positivity was detected in up to 50% of 
oropharyngeal (in Central Europe) and 35% of laryngeal 
cancers. However, recent studies on H&N cancers 
(specifically oropharyngeal cancer/cancer of the tonsil) have 
demonstrated that the presence of HPV DNA per se in 
invasive tumor tissues is insufficient proof for viral causality 
and could result in misclassification of malignant lesions and 
consequently, mistreatment of cancer patients. In addition, 
several studies have reported a better response to 
radiotherapy of HPV-driven oropharyngeal carcinomas, but 
not non-HPV-driven ones. Therefore, defining HPV-driven 
tumors by measuring markers of HPV-transformation in 
addition to HPV DNA, is crucial. Cervical squamous cell 
carcinoma (CSCC) is the best-understood model for HPV-
transformation, and up to 99% of HPV DNA positive CSSC are 
also HPV-driven. In addition to HPV DNA presence, CSCC is 
characterized by: (i) at least 1 viral genome copy present in 
each tumor cell (viral load), (ii) expression of viral oncogenes 
E6 and E7 (HPV RNA), and (iii) alteration of steady state 
levels of cellular proteins, most consistently up-regulation of 
p16INK4a. Outside of the cervix, this proof-of-principle marker 
combinations have been, to various extents, demonstrated 
for the cancer of the oropharynx, larynx, vulva and anus, 
with HPV16 being a leading transforming agent. In Central 
